{"title":"脊柱立体定向体外放射治疗后患放射性脊髓炎的风险","authors":"","doi":"10.1016/j.ijrobp.2024.07.056","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose/Objective(s)</h3><div>Stereotactic body radiation therapy (SBRT) for spinal metastases improves symptomatic outcomes and local control compared to conventional radiotherapy (RT). Treatment failure most often occurs within the epidural space, where dose is constrained by the risk of radiation myelitis (RM). We conducted a retrospective cohort study of patients treated with 3-fraction spine SBRT to create modern risk assessments of RM.</div></div><div><h3>Materials/Methods</h3><div>Patients were treated at a single institution between 2014 and 2023 with 3-fraction spine SBRT to a level between C1-L2. Patients were excluded if they had received overlapping prior RT, had less than 1 month of magnetic resonance imaging (MRI) follow up, or had a maximal dose to a voxel of spinal cord (Dmax) of 0 Gy. RM was defined as radiographic evidence of cord injury in the treatment field and further classified into grade (G) 1-4 or G3+ by Common Terminology Criteria for Adverse Events version 5.0. We assessed multiple dosimetric parameters of the true spinal cord structure for association with risk of RM. Univariable, cause-specific hazards, competing risk regression models were fit for RM using the Cox proportional hazards model with robust standard errors to account for patient-level clustering, with the dosimetric variables as predictors. To generate a dose-response model of RM, predicted probabilities and 95% confidence interval (CI) limits were estimated at 2 years using the regression models for the dosimetric variables of the minimum dose to the 0.1 cm<sup>3</sup> of spinal cord receiving the greatest dose (D0.1 cc) or Dmax.</div></div><div><h3>Results</h3><div>There were 1,423 patients treated to 1,904 segments in the analysis. Median follow up was 13 months (interquartile range 7-26 months). We identified 30 cases of RM, 19 of which were G3+. At 2 years, the cumulative incidence of G1-4 RM was 1.8% (95% CI = 1.2%-2.5%), and the rate of G3+ RM was 1.1% (95% CI = 0.71%-1.7%). For patients who experienced RM, the median time to myelitis was 10 months (range = 3.7-29.7 months). Cord D0.1 cc was the most important dosimetric predictor of RM on univariable, cause-specific hazards regression (for G3+ RM, hazard ratio (HR) = 2.14, 95% CI = 1.68-2.72, <em>P</em> < 0.0001). Dmax was also an important predictor of RM (for G3+ RM, HR = 1.82, 95% CI = 1.48-2.24, <em>P</em> < 0.0001). According to our dose-response model, a true cord D0.1 cc of 19.1 Gy and Dmax of 20.8 Gy predict a 1% risk (95% CI = 0.3%-1.6% and 0.4%-1.6%, respectively) of G3+ RM 2 years from SBRT.</div></div><div><h3>Conclusion</h3><div>This is the largest series of RM cases after spine SBRT. A true cord D0.1 cc constraint of 19.1 Gy and a Dmax constraint of 20.8 Gy correspond with a 1% risk of G3+ RM at 2 years.</div></div>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":null,"pages":null},"PeriodicalIF":6.4000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk of Radiation Myelitis after Hypofractionated Spine Stereotactic Body Radiation Therapy\",\"authors\":\"\",\"doi\":\"10.1016/j.ijrobp.2024.07.056\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose/Objective(s)</h3><div>Stereotactic body radiation therapy (SBRT) for spinal metastases improves symptomatic outcomes and local control compared to conventional radiotherapy (RT). Treatment failure most often occurs within the epidural space, where dose is constrained by the risk of radiation myelitis (RM). We conducted a retrospective cohort study of patients treated with 3-fraction spine SBRT to create modern risk assessments of RM.</div></div><div><h3>Materials/Methods</h3><div>Patients were treated at a single institution between 2014 and 2023 with 3-fraction spine SBRT to a level between C1-L2. Patients were excluded if they had received overlapping prior RT, had less than 1 month of magnetic resonance imaging (MRI) follow up, or had a maximal dose to a voxel of spinal cord (Dmax) of 0 Gy. RM was defined as radiographic evidence of cord injury in the treatment field and further classified into grade (G) 1-4 or G3+ by Common Terminology Criteria for Adverse Events version 5.0. We assessed multiple dosimetric parameters of the true spinal cord structure for association with risk of RM. Univariable, cause-specific hazards, competing risk regression models were fit for RM using the Cox proportional hazards model with robust standard errors to account for patient-level clustering, with the dosimetric variables as predictors. To generate a dose-response model of RM, predicted probabilities and 95% confidence interval (CI) limits were estimated at 2 years using the regression models for the dosimetric variables of the minimum dose to the 0.1 cm<sup>3</sup> of spinal cord receiving the greatest dose (D0.1 cc) or Dmax.</div></div><div><h3>Results</h3><div>There were 1,423 patients treated to 1,904 segments in the analysis. Median follow up was 13 months (interquartile range 7-26 months). We identified 30 cases of RM, 19 of which were G3+. At 2 years, the cumulative incidence of G1-4 RM was 1.8% (95% CI = 1.2%-2.5%), and the rate of G3+ RM was 1.1% (95% CI = 0.71%-1.7%). For patients who experienced RM, the median time to myelitis was 10 months (range = 3.7-29.7 months). Cord D0.1 cc was the most important dosimetric predictor of RM on univariable, cause-specific hazards regression (for G3+ RM, hazard ratio (HR) = 2.14, 95% CI = 1.68-2.72, <em>P</em> < 0.0001). Dmax was also an important predictor of RM (for G3+ RM, HR = 1.82, 95% CI = 1.48-2.24, <em>P</em> < 0.0001). According to our dose-response model, a true cord D0.1 cc of 19.1 Gy and Dmax of 20.8 Gy predict a 1% risk (95% CI = 0.3%-1.6% and 0.4%-1.6%, respectively) of G3+ RM 2 years from SBRT.</div></div><div><h3>Conclusion</h3><div>This is the largest series of RM cases after spine SBRT. A true cord D0.1 cc constraint of 19.1 Gy and a Dmax constraint of 20.8 Gy correspond with a 1% risk of G3+ RM at 2 years.</div></div>\",\"PeriodicalId\":14215,\"journal\":{\"name\":\"International Journal of Radiation Oncology Biology Physics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.4000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Radiation Oncology Biology Physics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0360301624008186\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0360301624008186","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Risk of Radiation Myelitis after Hypofractionated Spine Stereotactic Body Radiation Therapy
Purpose/Objective(s)
Stereotactic body radiation therapy (SBRT) for spinal metastases improves symptomatic outcomes and local control compared to conventional radiotherapy (RT). Treatment failure most often occurs within the epidural space, where dose is constrained by the risk of radiation myelitis (RM). We conducted a retrospective cohort study of patients treated with 3-fraction spine SBRT to create modern risk assessments of RM.
Materials/Methods
Patients were treated at a single institution between 2014 and 2023 with 3-fraction spine SBRT to a level between C1-L2. Patients were excluded if they had received overlapping prior RT, had less than 1 month of magnetic resonance imaging (MRI) follow up, or had a maximal dose to a voxel of spinal cord (Dmax) of 0 Gy. RM was defined as radiographic evidence of cord injury in the treatment field and further classified into grade (G) 1-4 or G3+ by Common Terminology Criteria for Adverse Events version 5.0. We assessed multiple dosimetric parameters of the true spinal cord structure for association with risk of RM. Univariable, cause-specific hazards, competing risk regression models were fit for RM using the Cox proportional hazards model with robust standard errors to account for patient-level clustering, with the dosimetric variables as predictors. To generate a dose-response model of RM, predicted probabilities and 95% confidence interval (CI) limits were estimated at 2 years using the regression models for the dosimetric variables of the minimum dose to the 0.1 cm3 of spinal cord receiving the greatest dose (D0.1 cc) or Dmax.
Results
There were 1,423 patients treated to 1,904 segments in the analysis. Median follow up was 13 months (interquartile range 7-26 months). We identified 30 cases of RM, 19 of which were G3+. At 2 years, the cumulative incidence of G1-4 RM was 1.8% (95% CI = 1.2%-2.5%), and the rate of G3+ RM was 1.1% (95% CI = 0.71%-1.7%). For patients who experienced RM, the median time to myelitis was 10 months (range = 3.7-29.7 months). Cord D0.1 cc was the most important dosimetric predictor of RM on univariable, cause-specific hazards regression (for G3+ RM, hazard ratio (HR) = 2.14, 95% CI = 1.68-2.72, P < 0.0001). Dmax was also an important predictor of RM (for G3+ RM, HR = 1.82, 95% CI = 1.48-2.24, P < 0.0001). According to our dose-response model, a true cord D0.1 cc of 19.1 Gy and Dmax of 20.8 Gy predict a 1% risk (95% CI = 0.3%-1.6% and 0.4%-1.6%, respectively) of G3+ RM 2 years from SBRT.
Conclusion
This is the largest series of RM cases after spine SBRT. A true cord D0.1 cc constraint of 19.1 Gy and a Dmax constraint of 20.8 Gy correspond with a 1% risk of G3+ RM at 2 years.
期刊介绍:
International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field.
This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.